GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » EV-to-FCF

Acurx Pharmaceuticals (Acurx Pharmaceuticals) EV-to-FCF : -2.63 (As of May. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Acurx Pharmaceuticals's Enterprise Value is $25.75 Mil. Acurx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.80 Mil. Therefore, Acurx Pharmaceuticals's EV-to-FCF for today is -2.63.

The historical rank and industry rank for Acurx Pharmaceuticals's EV-to-FCF or its related term are showing as below:

ACXP' s EV-to-FCF Range Over the Past 10 Years
Min: -16.26   Med: 0   Max: 0
Current: -2.63

ACXP's EV-to-FCF is ranked worse than
100% of 382 companies
in the Biotechnology industry
Industry Median: 5.84 vs ACXP: -2.63

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-07), Acurx Pharmaceuticals's stock price is $1.97. Acurx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.150. Therefore, Acurx Pharmaceuticals's PE Ratio for today is At Loss.


Acurx Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Acurx Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals EV-to-FCF Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -6.22 -4.93 -4.89

Acurx Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.93 -4.37 -3.52 -1.75 -4.89

Competitive Comparison of Acurx Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Acurx Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acurx Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's EV-to-FCF falls into.



Acurx Pharmaceuticals EV-to-FCF Calculation

Acurx Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=25.754/-9.802
=-2.63

Acurx Pharmaceuticals's current Enterprise Value is $25.75 Mil.
Acurx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acurx Pharmaceuticals  (NAS:ACXP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Acurx Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.97/-1.150
=At Loss

Acurx Pharmaceuticals's share price for today is $1.97.
Acurx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.150.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Acurx Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Acurx Pharmaceuticals (Acurx Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Executives
David P Luci director, 10 percent owner, officer: President and CEO
Robert J Deluccia director, 10 percent owner 40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer director 4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison director
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean director C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah officer: Chief Financial Officer C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue director C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305

Acurx Pharmaceuticals (Acurx Pharmaceuticals) Headlines